{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:56:57Z","timestamp":1790614617525,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.semarthrit.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T12:24:02Z","timestamp":1495542242000},"page":"409-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis"],"prefix":"10.1016","volume":"47","author":[{"given":"Konstantinos","family":"Ntelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Solomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatis-Nick","family":"Liossis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.05.004_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jbspin.2014.10.010","article-title":"Systemic sclerosis: recent insights","volume":"82","author":"Elhai","year":"2015","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","article-title":"Systemic sclerosis and localized scleroderma\u2014current concepts and novel targets for therapy","volume":"38","author":"Distler","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5301\/jsrd.5000207","article-title":"Emerging strategies for treatment of systemic sclerosis","volume":"1","author":"Khanna","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib5","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis","volume":"311","author":"van Laar","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/BOR.0b013e3282eeb3a4","article-title":"Platelet contributions to the pathogenesis of systemic sclerosis","volume":"19","author":"Postlethwaite","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fimmu.2012.00160","article-title":"The role of platelets in the pathogenesis of systemic sclerosis","volume":"3","author":"Ramirez","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib9","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1172\/JCI26891","article-title":"The biogenesis of platelets from megakaryocyte proplatelets","volume":"115","author":"Patel","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9060143","article-title":"Platelet activation: the mechanisms and potential biomarkers","volume":"2016","author":"Yun","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib11","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","article-title":"Mechanisms of thrombus formation","volume":"359","author":"Furie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib12","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/j.1538-7836.2003.00479.x","article-title":"Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1)","volume":"1","author":"Marcus","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2008.003178","article-title":"Platelet receptors and signaling in the dynamics of thrombus formation","volume":"94","author":"Rivera","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2036.1997.153328000.x","article-title":"Review article: platelets in inflammatory bowel disease\u2014pathogenetic role and therapeutic implications","volume":"11","author":"Collins","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrrheum.2012.118","article-title":"Platelets: active players in the pathogenesis of arthritis and SLE","volume":"8","author":"Boilard","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2174\/138161282004140213143843","article-title":"Platelets in rheumatic diseases: friend or foe?","volume":"20","author":"Gasparyan","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00296-010-1446-x","article-title":"Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2015-208442","article-title":"Anti-TNF\u03b1 agents curb platelet activation in patients with rheumatoid arthritis","volume":"75","author":"Manfredi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/ATVBAHA.116.308126","article-title":"Activated platelets induce endothelial cell activation via an interleukin-1\u03b2 pathway in systemic lupus erythematosus","volume":"37","author":"Nhek","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4049\/jimmunol.1200580","article-title":"Platelets present antigen in the context of MHC class I","volume":"189","author":"Chapman","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1317","article-title":"Platelets mediate cytotoxic T lymphocyte-induced liver damage","volume":"11","author":"Iannacone","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib22","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1136\/gut.52.10.1435","article-title":"Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients","volume":"52","author":"Danese","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/heart.86.6.649","article-title":"Patients with acute coronary syndromes express enhanced CD40 ligand\/CD154 on platelets","volume":"86","author":"Garlichs","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2003-07-2367","article-title":"Platelet-associated CD154 in immune thrombocytopenic purpura","volume":"105","author":"Solanilla","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib25","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.exphem.2007.05.021","article-title":"Human platelets can activate peripheral blood B cells and increase production of immunoglobulins","volume":"35","author":"Cognasse","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1074-7613(03)00177-8","article-title":"Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments","volume":"19","author":"Elzey","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib27","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2010-01-261206","article-title":"Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis","volume":"116","author":"Lievens","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/09537104.2011.595850","article-title":"Platelet-derived microparticles cause CD154-dependent activation of dendritic cells","volume":"23","author":"Nomura","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib29","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.4049\/jimmunol.1303239","article-title":"Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases","volume":"192","author":"Xie","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00005-009-0032-y","article-title":"Platelet influence on T- and B-cell responses","volume":"57","author":"Sowa","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib31","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1097\/01.ASN.0000029588.07166.20","article-title":"Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40\/CD40 ligand pathway and may amplify glomerular injury","volume":"13","author":"Tanaka","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib32","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood.V126.23.3448.3448","article-title":"Platelets from patients with myocardial infarction can activate T cells in vitro","volume":"126","author":"Solomou","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib33","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1161\/ATVBAHA.107.160218","article-title":"Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function","volume":"28","author":"Zimmerman","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib34","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.4049\/jimmunol.143.12.4015","article-title":"Activated platelets express IL-1 activity","volume":"143","author":"Hawrylowicz","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1160\/TH07-11-0685","article-title":"Platelet-vessel wall interactions in atherosclerotic disease","volume":"99","author":"Langer","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0021-9150(99)00241-5","article-title":"Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis","volume":"148","author":"Gawaz","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1357-2725(96)00159-8","article-title":"Nuclear factor-\u03baB","volume":"29","author":"Barnes","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib39","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/S0021-9258(17)40535-7","article-title":"Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets","volume":"252","author":"Rudnick","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signaling system: from basic understanding to drug development for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jbmr.2724","article-title":"Decreased serotonin levels and serotonin-mediated osteoblastic inhibitory signaling in patients with ankylosing spondylitis","volume":"31","author":"Klavdianou","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","article-title":"Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum","volume":"135","author":"Yadav","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/intimm\/dxh242","article-title":"5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes","volume":"17","author":"D\u00fcrk","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib45","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2006-10-052787","article-title":"Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor","volume":"109","author":"Le\u00f3n-Ponte","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2006.08.004","article-title":"5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes","volume":"181","author":"Yin","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.intimp.2010.10.007","article-title":"Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor","volume":"11","author":"Inoue","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jneuroim.2013.06.006","article-title":"Citalopram suppresses thymocyte cytokine production","volume":"262","author":"Shenoy","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib49","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s11481-013-9463-7","article-title":"Fluoxetine reduces murine graft-versus-host disease by induction of T cell immunosuppression","volume":"8","author":"Gobin","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib50","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.4049\/jimmunol.177.7.4810","article-title":"A role for inflammatory mediators in the induction of immunoregulatory B cells","volume":"177","author":"Matsumura","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1533-2500.2009.00259.x","article-title":"Citalopram enhances B cell numbers in a murine model of morphine-induced immunosuppression","volume":"9","author":"Nguyen","year":"2009","journal-title":"Pain Pract"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000292646","article-title":"Serotonin receptor 3A expression in normal and neoplastic B cells","volume":"77","author":"Rinaldi","year":"2010","journal-title":"Pathobiology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V68.3.627.627","article-title":"Quantitative analysis of platelet surface HLA by W6\/32 anti-HLA monoclonal antibody","volume":"68","author":"Kao","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib54","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1166296","article-title":"Platelets kill intraerythrocytic malarial parasites and mediate survival to infection","volume":"323","author":"McMorran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1160\/TH14-05-0455","article-title":"Neutrophil extracellular traps (NETs) and the role of platelets in infection","volume":"112","author":"Andrews","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib56","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1160\/TH13-02-0102","article-title":"Crosstalk between platelets and the complement system in immune protection and disease","volume":"110","author":"Verschoor","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib57","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.4049\/jimmunol.172.8.4964","article-title":"Mast cell-independent mechanisms of immediate hypersensitivity: a role for platelets","volume":"172","author":"Cara","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.157.2.557","article-title":"Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity","volume":"157","author":"Geba","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00070","article-title":"Are platelets cells? And if yes, are they immune cells?","volume":"6","author":"Garraud","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib60","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.it.2004.07.003","article-title":"Platelets: signaling cells in the immune continuum","volume":"25","author":"Weyrich","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib61","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/trf.12068","article-title":"Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model","volume":"53","author":"Lee","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib62","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1016\/S0021-9258(18)32345-7","article-title":"Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization","volume":"258","author":"Assoian","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6101(99)00037-4","article-title":"TGF-\u03b2 in blood: a complex problem","volume":"11","author":"Grainger","year":"2000","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib64","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/clim.2001.5008","article-title":"Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment","volume":"99","author":"Sime","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib65","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib66","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2011-09-377648","article-title":"Platelet TGF-\u03b21 contributions to plasma TGF-\u03b21, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload","volume":"119","author":"Meyer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib67","first-page":"555","article-title":"The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells","volume":"27","author":"Bachem","year":"1989","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/jb\/mvh126","article-title":"Abundant retention and release of connective tissue growth factor (CTGF\/CCN2) by platelets","volume":"136","author":"Kubota","year":"2004","journal-title":"J Biochem"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib70","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/ar3879","article-title":"B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin","volume":"14","author":"Daoussis","year":"2012","journal-title":"Arthritis ResTher"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib71","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":"Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0002-9440(10)65115-2","article-title":"Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats","volume":"155","author":"Rice","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib73","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib74","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.devcel.2008.12.003","article-title":"Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis","volume":"16","author":"Olson","year":"2009","journal-title":"Dev Cell"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib75","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma","volume":"92","author":"Gay","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib76","first-page":"1876","article-title":"Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma","volume":"22","author":"Ludwicka","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3181\/00379727-191-42880","article-title":"Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis","volume":"191","author":"Pandolfi","year":"1989","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib78","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/jcmm.12419","article-title":"Emerging role of HMGB1 in fibrotic diseases","volume":"18","author":"Li","year":"2014","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib79","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10875-008-9252-x","article-title":"Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity","volume":"29","author":"Yoshizaki","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib80","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib81","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrendo.2009.51","article-title":"Fibrosis and carcinoid syndrome: from causation to future therapy","volume":"5","author":"Druce","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib82","first-page":"321","article-title":"Pulmonary platelet trapping induced by bleomycin: correlation with fibrosis and involvement of the beta 2 integrins","volume":"75","author":"Piguet","year":"1994","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib83","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2015-02-622233","article-title":"Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1\/VCAM-1-mediated neutrophilic acute lung inflammation","volume":"126","author":"Guo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib84","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical Wnt signalling is required for TGF-\u03b2-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib85","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1053\/j.gastro.2010.02.054","article-title":"Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice","volume":"138","author":"Kodama","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib86","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1123842","article-title":"Platelet-derived serotonin mediates liver regeneration","volume":"312","author":"Lesurtel","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib87","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/tri.12163","article-title":"Clopidogrel reduces post-transplant obliterative bronchiolitis","volume":"26","author":"Preidl","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib88","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/hepr.12140","article-title":"Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis","volume":"44","author":"Saito","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib89","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/gut.2007.144550","article-title":"Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease","volume":"57","author":"Fujita","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib90","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.1780271009","article-title":"Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin","volume":"27","author":"Beckett","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12891-016-1072-1","article-title":"Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study","volume":"17","author":"Ntelis","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1620\/tjem.229.213","article-title":"Platelet transfusion improves liver function in patients with chronic liver disease and cirrhosis","volume":"229","author":"Maruyama","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib93","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","article-title":"Raynaud\u2019s phenomenon: pathogenesis and management","volume":"59","author":"Bakst","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib94","first-page":"221","article-title":"The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud\u2019s phenomenon associated with systemic connective tissue diseases","volume":"25","author":"Rychlik-Golema","year":"2006","journal-title":"Int Angiol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/030097401753180372","article-title":"Relative roles of endothelial cell damage and platelet activation in primary Raynaud\u2019s phenomenon (RP) and RP secondary to systemic sclerosis","volume":"30","author":"Silveri","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/bjs.1800760430","article-title":"Plasma eicosanoids, platelet function and cold sensitivity","volume":"76","author":"Wilkinson","year":"1989","journal-title":"Br J Surg"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib97","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00561375","article-title":"Ketanserin treatment and serotonin in patients with primary and secondary Raynaud\u2019s phenomenon","volume":"35","author":"Marasini","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1346-8138.2000.tb02246.x","article-title":"Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud\u2019s phenomenon after long-term treatment with a 5-HT2 receptor antagonist","volume":"27","author":"Igarashi","year":"2000","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib99","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib100","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","author":"Kowal-Bielecka","year":"2016","journal-title":"Ann Rheum Dis annrheumdis"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib101","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00296-006-0254-9","article-title":"Citalopram-induced Raynaud\u2019s phenomenon","volume":"27","author":"Peir\u00f3","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib102","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/000331979604700909","article-title":"Digital infarction in a patient with Raynaud\u2019s phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report","volume":"47","author":"Bell","year":"1996","journal-title":"Angiology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib103","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jcp.42.7.716","article-title":"Abnormal platelet aggregation in patients with Raynaud\u2019s phenomenon","volume":"42","author":"Biondi","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib104","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.1993.tb03145.x","article-title":"Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis","volume":"84","author":"Goodfield","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/000331978603700802","article-title":"Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud\u2019s phenomenon","volume":"37","author":"Destors","year":"1986","journal-title":"Angiology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib106","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/ard.50.8.567","article-title":"In vitro platelet aggregability studies: lack of evidence for platelet hyperactivity in systemic sclerosis","volume":"50","author":"Price","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib107","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/000331979004101112","article-title":"Platelet aggregation is not necessary for occurrence of Raynaud\u2019s phenomenon: a clinical history and laboratory results","volume":"41","author":"Bellucci","year":"1990","journal-title":"Angiology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib108","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.drudis.2014.04.001","article-title":"Thrombosis, platelets, microparticles and PAH: more than a clot","volume":"19","author":"Lannan","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00001721-199603000-00029","article-title":"Platelet aggregation in patients with primary pulmonary hypertension","volume":"7","author":"Nakonechnicov","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib110","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/000331979304400905","article-title":"Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension","volume":"44","author":"Lopes","year":"1993","journal-title":"Angiology"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib111","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1378\/chest.104.6.1690","article-title":"Platelet activation and fibrinopeptide formation in pulmonary hypertension","volume":"104","author":"Schulman","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib112","first-page":"9700","article-title":"Platelet abnormalities in chronic thromboembolic pulmonary hypertension","volume":"8","author":"Remkov\u00e1","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib113","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib114","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herv\u00e9","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib115","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","article-title":"Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry","volume":"80","author":"Pietra","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib116","first-page":"L46","article-title":"Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture","volume":"266","author":"Lee","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/eci.12018","article-title":"Small platelet microparticle levels are increased in pulmonary arterial hypertension","volume":"43","author":"Nadaud","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib118","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/2045-8932.114760","article-title":"On the origin of microparticles: from \u201cplatelet dust\u201d to mediators of intercellular communication","volume":"3","author":"Hargett","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib119","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3109\/08916934.2012.719946","article-title":"Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis","volume":"45","author":"Maugeri","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib120","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1089\/ars.2013.5298","article-title":"Oxidative stress elicits platelet\/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis","volume":"20","author":"Maugeri","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib121","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1152\/ajplung.00378.2006","article-title":"Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension","volume":"293","author":"Arciniegas","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib122","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1537-2995.2008.01862.x","article-title":"Quantitative assessment of the kinetics of growth factors release from platelet gel","volume":"48","author":"Su","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib124","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":"The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib125","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cjca.2014.04.016","article-title":"Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis","volume":"30","author":"Caldeira","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib126","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1161\/CIRCULATIONAHA.110.015693","article-title":"Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT","volume":"123","author":"Kawut","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.semarthrit.2017.05.004_bib127","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib128","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13075-015-0848-2","article-title":"Inhibition of angiogenesis by platelets in systemic sclerosis patients","volume":"17","author":"Hirigoyen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1172\/JCI119560","article-title":"Cloning, characterization, and functional studies of a nonintegrin platelet receptor for type I collagen","volume":"100","author":"Chiang","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib131","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1172\/JCI119741","article-title":"A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type I collagen-mediated platelet aggregation","volume":"100","author":"Chiang","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2017.05.004_bib132","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.thromres.2005.03.003","article-title":"Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis","volume":"117","author":"Chiang","year":"2006","journal-title":"Thromb Res"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217301105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217301105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T14:08:00Z","timestamp":1692799680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217301105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0049017217301105"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.05.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}